SAB Biotherapeutics (SABS) Current Assets (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Current Assets data on file, last reported at $112.8 million in Q1 2026.

• Quarterly Current Assets rose 592.05% year-over-year to $112.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $112.8 million (up 592.05% YoY) and the FY2025 annual result came in at $101.1 million, up 324.73% from the prior year.
• Current Assets climbed to $112.8 million in Q1 2026, from $101.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $113.3 million in Q3 2025 to a low of $3.1 million in Q3 2023.
• A 5-year average of $40.7 million and a median of $28.0 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets surged 3218.15% — and 2023, when it slumped 85.9%.
• Tracing SABS's Current Assets over 5 years: stood at $22.1 million in 2022, then surged by 166.58% to $58.9 million in 2023, then sank by 59.61% to $23.8 million in 2024, then soared by 324.73% to $101.1 million in 2025, then grew by 11.61% to $112.8 million in 2026.
• The last three Current Assets figures came in at $112.8 million (Q1 2026), $101.1 million (Q4 2025), and $113.3 million (Q3 2025), per Business Quant data.